New Bone-Forming Agents
Pharmacological interventions for patients with osteoporosis aim at decreasing the risk of fractures and associated clinical consequences by correcting the imbalance between bone resorption and bone formation that constitutes the pathophysiological basis of the disease. Despite the availability of efficacious treatments for fracture reduction, there are still unmet needs requiring a broader range of therapeutics. In particular, there is a need for agents capable of replacing already lost bone and of drastically reducing the risk of non-vertebral fractures, the most frequent fragility fractures. In recent years, new molecules and therapeutic targets have been identified, and many were investigated as potential treatments for osteoporosis. This chapter briefly reviews newly developed bone-forming agents.
KeywordsOsteoporosis Bone resorption Bone formation Fragility fracture Parathyroid hormone (PTH) peptides Sclerostin inhibitors Romosozumab